Alumis (ALMS) traded sharply lower on Tuesday after the company’s lead asset, envudeucitinib, failed in a mid-stage trial for patients with systemic lupus erythematosus, an autoimmune condition affecting skin, joints, and other organs.
The setback comes as Alumis (ALMS